- Why Cryoport
- Who We Serve
- About Us
- News & Events
- Investor Relations
- Contact Us
Are your advanced therapy supply chains ready for this year’s 4G/LTE data management transition?
A leap forward in standardizing the regenerative medicine supply chain
Date: December 5-8, 2022
Location: Amsterdam, The Netherlands
Date: December 10-13, 2022
Location: New Orleans, LA
Cryoport combines its expertise in temperature-controlled supply chain solutions to develop a comprehensive offering of vein-to-vein services, one of which includes Kit Production. From clinical to commercial, our team works directly with your team to curate the specific kitting components for manufacturing, testing and clinical use. Developing a standardized and high-quality kitting solution requires the same level of attention as every other step in the collection, transportation and distribution process. In order to mitigate risk when focusing on kitting, it is imperative that all components are centrally managed and distributed. Cryoport has an experienced team that can work with you to develop a custom blood sample kit that fits your clinical or commercial needs. Implementing a centrally managed kitting solution helps to maximize the quality of your biological samples. It reduces inconsistencies in labels, vials, needles, tubes and other kit components, while also reducing unforeseen variables such as expiration dates and lot numbers for all global collections.
Companies vying to be the first to market with breakthrough treatments have a great deal riding on the success of their efforts. Incorporating innovative processes, ethical considerations, assuring the safety and efficacy of the product, and managing the commodity's environmental control are formidable challenges that often lack standardized quality control procedures. Precision medicine requires end-to-end traceability: everything from chain of custody, to chain of condition, to chain of identity. The fragility of regenerative medicine therapies and the need to manage risk means a fourth link in the chain will soon be a regulatory requirement.